Abstract
Use of neoadjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors to downstage inoperable, non-metastatic, oestrogen receptor positive, HER2-negative breast cancer
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
